Liver Cancer

A living liver donor shares recovery challenges, emotional rewards and advice for those considering donation to help save a life.

A son shares his decision to become a living liver donor, offering his father a second chance after a cancer diagnosis.

PLT012 received FDA fast track status for liver cancer, with an ongoing trial evaluating safety and early activity of the CD36-targeting immunotherapy.

Charles Walker discusses living liver donation, survivorship challenges and why self-advocacy and awareness are vital for patients with liver cancer

Charles Walker joins CURE’s Gina Mauro to share his long and road to a liver cancer diagnosis and the importance of being your own medical advocate.

The FDA granted fast track designation to irpagratinib for previously treated advanced hepatocellular carcinoma with FGF19 overexpression.

CURE spoke with advocate Karen Hoyt about liver cancer, liver disease, and liver health, highlighting silent risk, misconceptions and need for awareness.

In this Q&A, Emma and Paul share how self-advocacy and communication shaped their experience with hepatocellular carcinoma after an unexpected diagnosis.

Dr. Anjana Pillai says treatment depends on stage and health, with surgery, transplant, local therapy or systemic drugs to help people live longer.

Advances in systemic and local therapies are helping more live longer with liver cancer and move forward after treatment as survivorship becomes a key focus.

During Liver Cancer Awareness Month, Dr. Anjana Pillai says more treatment options, growing trials and ongoing research offer hope for patients.

Dr Anjana Pillai explains screening, imaging and biopsy for liver cancer, why staging matters and which questions help patients understand care.

Tiragolumab added to Tecentriq plus Avastin did not improve progression-free survival in untreated advanced hepatocellular carcinoma, phase 3 data show.

Dr. Anjana Pillai explains that staging liver cancer involves assessing tumor size, spread, and vessel involvement to guide treatment.

Dr. Anjana Pillai explains liver cancer types, risk factors, and prevention, stressing early screening for high-risk patients with liver disease.

Dr. Anjana Pillai highlights Liver Cancer Awareness Month’s role in promoting liver health, dispelling myths and encouraging early detection and care.

This guide is designed to help you understand liver cancer and equip you with the right questions to ask your medical team.

The incidence of hepatocellular carcinoma has risen between 2010 and 2019; however, for people under 50 years of age, the proportion of cases has declined.

The FDA approved SIR-Spheres Y-90 resin microspheres for unresectable liver cancer, the only radioembolization approved in the U.S. for both HCC and mCRC.

Two people connect by sharing their experiences about taking care of their spouses who died from cancer, and the realization that sparked something more.

The FDA has approved Opdivo with Yervoy for the first-line treatment of adults with unresectable or metastatic hepatocellular carcinoma.

For patients with unresectable, non-metastatic hepatocellular carcinoma, Lenvima plus Keytruda in combination with TACE improved outcomes.

SBRT improved local progression-free survival over RFA in small recurrent HCC, particularly in tumors 2 cm or less.

Opdivo plus Yervoy shows efficacy and manageable safety as first-line treatment for unresectable hepatocellular carcinoma in the CheckMate 9DW study.

CURE spoke with an expert about the potential positive effects of radiation therapy for patients with hepatocellular carcinoma.